| Migraine Disorders
Qulipta vs Ubrelvy
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Qulipta vs Ubrelvy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUbrelvy has a higher rate of injection site reactions vs Qulipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ubrelvy but not Qulipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qulipta
Ubrelvy
At A Glance
Oral
Daily
CGRP receptor antagonist
Oral
As needed
CGRP receptor antagonist
Indications
- Migraine Disorders
- Migraine Disorders
Dosing
Migraine Disorders (episodic) 10 mg, 30 mg, or 60 mg taken once daily orally, with or without food.
Migraine Disorders (chronic) 60 mg taken once daily orally, with or without food.
Migraine Disorders 50 mg or 100 mg orally as needed; a second dose may be taken at least 2 hours after the initial dose; maximum 200 mg per 24-hour period. Dose reductions apply with moderate or weak CYP3A4 inhibitors, BCRP and/or P-gp only inhibitors, and in patients with severe hepatic or severe renal impairment (CLcr 15-29 mL/min); avoid in end-stage renal disease.
Contraindications
- History of hypersensitivity to atogepant or any of the components of QULIPTA (reactions have included anaphylaxis and dyspnea)
- Concomitant use of strong CYP3A4 inhibitors
- History of serious hypersensitivity to ubrogepant or any component of UBRELVY (reactions have included anaphylaxis, dyspnea, and facial or throat edema)
Adverse Reactions
Most common (>=4%) Nausea, constipation, fatigue/somnolence
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity (anaphylaxis, dyspnea, rash, pruritus, urticaria, facial edema), hypertension, Raynaud's phenomenon
Most common (>=2%) Nausea, somnolence, dry mouth
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity (anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, pruritus), hypertension, Raynaud's phenomenon
Pharmacology
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology and is indicated for preventive treatment of migraine in adults.
Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; by blocking CGRP receptor signaling it inhibits a pathway implicated in migraine pathophysiology.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qulipta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Ubrelvy
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (12/12) · Qty limit (12/12)
UnitedHealthcare
Qulipta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Ubrelvy
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Qulipta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Ubrelvy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QuliptaView full Qulipta profile
UbrelvyView full Ubrelvy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.